Australasian Dentist Issue 93

CATEGORY AUSTRALASIAN DENTIST 115 COMPANY PROFIL S Q What can you tell us about Citrox® and its potential uses as an ingredient in the formulation of antiseptic mouthwashes, gel and toothpaste? In the last few years, phytopharmaceuticals havebeenrecognisedtohaveanoutstanding role in new drug delivery. Bioflavonoids are polyphenolic compounds, found in plants, with proven health benefits. Citrox® is a soluble formulation that contains natural bioflavonoid complex, derived from the Citrus aurantius (bitter orange), and organic acids. Studies have shown its strong antimicrobial, anti-inflammatory, and anti-oxidative potential. Citrox® has broad antimicrobial spectrumand is very effective against bacteria, viruses, and fungi. Its mechanisms of action on cellular level are very similar to CHX. In addition, Citrox® can attenuate microbial pathogenicity by targeting their enzymes and virulence factors, thus reducing their potential to cause disease. This property is of importance in combating CHX resistant microorganisms that have developed tolerance against certain antibiotics. Used in combination with CHX in PerioPlus+, Citrox® demonstrated synergistic activity, whichmay enable using lower concentrations of CHX in oral health products and subsequently a reduction of its adverse effects. We believe that Citrox® is proving itself as an important ingredient in efficient mouth wash solutions and together with cyclodextrins, will play a crucial role in the future of oral healthcare. Q Based on your study on tooth staining caused by commercial mouthwashes, do you think Citrox® can help to counter the issue? If so, how? Reducing concentration of CHX and supplementing it with another potential antiseptic such as Citrox®, may result in reduced side effects, whilst maintaining antimicrobial properties. Our in vitro study tested discoloration potential of PerioPlus+ mouthwashes on direct aesthetic restorative materials such as composite resins and glass ionomer cements. In our tests, PerioPlus+ mouthwashes caused less staining in specimens of the tested aesthetic materials, as compared to similar concentrations of CHX. While the initial results look promising, these are still early days, and further studies are necessary to elucidate the role of Citrox® in reduction or prevention of staining. Q Does your research on Perio Plus show it is as step in the right direction when it comes to designing the “rinse” of the future? Positive results of in vitro studies demonstrated the potential of PerioPlus+ to overcome some of the drawbacks of CHX. However clinical studies are necessary to confirm in vitro results and to further explore various indications for its clinical use. Currently, we are designing clinical studies with our colleagues from Europe, and the University of Sydney will be one of the first centres to test PerioPlus+ mouth washes in the clinical settings. We also aim to continue exploring various natural ingredients that might set standards for the future oral healthcare products. u References: Hooper SJ, Lewis MA, Wilson MJ, Williams DW. Antimicrobial activity of Citrox bioflavonoid preparations against oral microorganisms. Br Dent J. 2011 Jan 8;210(1):E22. doi: 10.1038/sj.bdj.2010.1224. PMID: 21217705 Jeyakumar J, Sculean A, Eick S. Anti-biofilm Activity of Oral Health-care Products Containing Chlorhexidine Digluconate and Citrox. Oral Health Prev Dent. 2020 Oct 27;18(1):981-990. doi: 10.3290/j. ohpd.a45437. PMID: 33215489 Malic S et al. Antimicrobial activity of novel mouthrinses against planktonic cells and biofilms of pathogenic microorganisms. Microbiology Discovery 2013 Microbiology Discovery. Doi:10.7243/2052-6180-1-11. At Dental Brokers Australia, we specialise in dental practice sales with experience in structured exit strategies. Even if you wish to continue working for the future years, we can help ensure your transition process to settlement is smooth and stress free. With over 25 years of assisting Practice Managers and Practice Principles in their growth and profitability, when it comes time for a principle to transition their dental practice, numerous decisions have to be addressed. Transitioning a dental practice will be one of the largest business decisions a dentist will have to go through. At Dental Brokers Australia, we take pride in our personal approach ensuring that it’s a perfect fit for a perfect transition. 0418 845 308 rachel@dbaust.com.au OUR PROCESS Rachel Garel, Director scan here to register Dr Tihana Divnic-Resnik is a Senior Lecturer at the University of Sydney. For 10 years, she served as lecturer in Periodontics and Oral Medicine at the University of Belgrade, Serbia, where she also practised as a specialist of Periodontology and Oral Medicine. She currently practices at the Department for Periodontics at Sydney Dental Hospital. Dr Divnic-Resnik holds a master’s degree and PhD in Periodontology.